Climate Change Data

Intra-Cellular Therapies, Inc.

Climate Impact & Sustainability Data (2022, 2023)

Reporting Period: 2022

Environmental Metrics

ESG Focus Areas

  • Waste Management
  • Climate Change
  • Occupational Health, Safety & Development
  • Patient Welfare, Engagement & Advocacy
  • Access & Affordability
  • Drug Safety
  • Cyber Security & Data Privacy
  • Business Ethics
  • Community Involvement & Philanthropy
  • Supply Chain Management

Environmental Achievements

  • Transitioned from blister pack to bottle product packaging, maximizing product utilization and reducing waste.
  • Launched 42mg product with a significant shelf-life, minimizing waste by providing ample distribution time.

Social Achievements

  • Maintained 12% annual employee turnover in 2022.
  • Implemented a wellness program fostering mindfulness and well-being.
  • Engaged with patient advocacy organizations (PAOs) to improve patient outcomes.
  • Established a Patient Assistance Program (PAP) to support patients with financial difficulties.

Governance Achievements

  • Reported zero monetary losses from corruption and bribery legal proceedings.
  • Implemented a comprehensive suite of policies to ensure ethical conduct.
  • Established a third-party whistleblower hotline.

Climate Goals & Targets

Long-term Goals:
  • Report Scope 1 & 2 GHG emissions in alignment with SEC compliance.
Medium-term Goals:
  • Transition towards low carbon transport.
  • Integrate climate-related risks and opportunities into annual Enterprise Risk Assessment (ERA).
Short-term Goals:
  • Identify and assess ESG risks, including climate-related risks.

Environmental Challenges

  • Potential climate change impacts on operations, supply chain, and customers.
  • Ensuring supply chain resilience against global disruptions.
Mitigation Strategies
  • Implemented inventory placement strategy to limit disruptions due to weather-related events.
  • Incorporated disaster risk assessments into supplier audits and established secondary sources at every level of the supply chain.
  • Exploring greener alternatives for company cars.
  • Leveraging third-party logistics (3PL) services to minimize carbon footprint.
  • Preparing for amendments to the Drug Supply Chain Security Act (DSCSA) to reintroduce returned products into stock.

Supply Chain Management

Supplier Audits: Routine, with occasional engagement of external consultants.

Responsible Procurement
  • Adherence to standards set by the FDA and regional health authorities.

Climate-Related Risks & Opportunities

Physical Risks
  • Extreme weather events
Opportunities
  • Transitioning towards low carbon transport

Reporting Standards

Frameworks Used: SASB, TCFD

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:200,069 KWh (total business)
Water Consumption:0.6 ML (total)
Waste Generated:2.5 US tons (total, including medical and hazardous)
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Environmental Stewardship
  • Social Responsibility & Well-being
  • Governance

Environmental Achievements

  • Reduced waste through process optimization and greener chemistry in manufacturing.
  • 25% of total waste (excluding medical and hazardous waste) recycled.
  • Adopted nitrogen generator technology, eliminating the need for nitrogen tanks and associated emissions.

Social Achievements

  • Increased patient assistance programs, providing approximately $16 million in free products.
  • Supported the Miami Foundation for Mental Health, establishing a community resource model.
  • Decreased employee turnover rate from 12% in 2022 to 10% in 2023.
  • Over 90% of commercial employees reported being proud to work at the company and nearly 90% recommend ITCI as a good place to work.

Governance Achievements

  • Maintained high governance standards and compliance throughout operations.
  • Implemented robust anti-counterfeiting measures for products.
  • Developed plans to strategically hold API in multiple locations across the US.

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Managing chemical waste generated during manufacturing processes.
  • Ensuring supply chain resilience amidst global disruptions.
  • Maintaining high safety standards in clinical trials and post-market phases.
Mitigation Strategies
  • Working with on-site chemical waste management partners for safe disposal.
  • Implementing geographical diversity and safety stock in the supply chain.
  • Rigorous compliance with FDA standards and GxP guidelines, continuous monitoring and reporting of adverse drug events.

Supply Chain Management

Supplier Audits: Routine audits, occasionally with external consultants.

Responsible Procurement
  • Collaboration with reputable CMOs, due diligence, and adherence to ethical standards.

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: SASB, TCFD

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed